Company / PP&E (Net)
Spyre Therapeutics, Inc. PP&E (Net) History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
-
FY2023
5-year range
$0 / $4.5M
FY2019-FY2023
Trend
-100.0%
vs FY2022
Sector context
#194 of 193
Health Care
What the data says
Declined from $5M to $0 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom -1% in Health CareTop 101% of 193
▼
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- In FY2023, pp&e (net) decreased 100.0% year-over-year.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $3.2M | -29.2% |
| FY2021 | $4.5M | -19.4% |
| FY2020 | $5.6M | +136.6% |
| FY2019 | $2.4M | +134.3% |
| FY2018 | $1.0M | +19.2% |
| FY2017 | $854.0K | +42.6% |
| FY2016 | $599.0K | +72.1% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026